Taylor Hoffman Wealth Management Acquires 190 Shares of Illumina, Inc. (NASDAQ:ILMN)

Taylor Hoffman Wealth Management lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 42.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 633 shares of the life sciences company’s stock after acquiring an additional 190 shares during the period. Taylor Hoffman Wealth Management’s holdings in Illumina were worth $193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the company. Baillie Gifford & Co. raised its position in shares of Illumina by 5.0% in the 2nd quarter. Baillie Gifford & Co. now owns 16,775,175 shares of the life sciences company’s stock worth $6,175,781,000 after acquiring an additional 799,884 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Illumina by 5.2% in the 2nd quarter. Jennison Associates LLC now owns 5,976,219 shares of the life sciences company’s stock worth $2,200,145,000 after buying an additional 296,541 shares during the last quarter. Edgewood Management LLC boosted its stake in shares of Illumina by 1.1% in the 2nd quarter. Edgewood Management LLC now owns 4,157,827 shares of the life sciences company’s stock worth $1,530,704,000 after buying an additional 46,899 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Illumina by 67,829.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 2,260,705 shares of the life sciences company’s stock worth $832,279,000 after buying an additional 2,257,377 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Illumina by 1.3% in the 2nd quarter. Northern Trust Corp now owns 1,682,543 shares of the life sciences company’s stock worth $619,428,000 after buying an additional 21,782 shares during the last quarter. 90.94% of the stock is owned by hedge funds and other institutional investors.

ILMN stock traded down $1.86 during midday trading on Friday, reaching $293.39. 935,600 shares of the company’s stock traded hands, compared to its average volume of 1,040,401. The firm has a market capitalization of $44.23 billion, a PE ratio of 51.29, a price-to-earnings-growth ratio of 2.22 and a beta of 1.03. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.15 and a current ratio of 6.82. Illumina, Inc. has a 52 week low of $263.30 and a 52 week high of $380.76. The company has a 50-day moving average price of $302.08 and a two-hundred day moving average price of $310.65.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 24th. The life sciences company reported $1.93 EPS for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.53. The business had revenue of $907.00 million for the quarter, compared to analysts’ expectations of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.52 earnings per share. As a group, analysts predict that Illumina, Inc. will post 6.44 EPS for the current fiscal year.

In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $288.36, for a total transaction of $951,588.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Oene Mark Van sold 625 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $304.84, for a total transaction of $190,525.00. Following the sale, the senior vice president now owns 14,209 shares of the company’s stock, valued at $4,331,471.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,638 shares of company stock valued at $9,580,415. Company insiders own 0.38% of the company’s stock.

ILMN has been the topic of several research analyst reports. UBS Group upped their price objective on Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Credit Suisse Group reiterated a “buy” rating and issued a $340.00 price objective on shares of Illumina in a research note on Wednesday, July 31st. Piper Jaffray Companies dropped their price objective on Illumina from $348.00 to $341.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Cowen set a $320.00 price objective on Illumina and gave the company a “buy” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $333.38.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: Net Income

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit